Skip to main content

Advertisement

Log in

Applicability of the EORTC/MSG criteria for IFD in clinical practice

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Invasive fungal disease (IFD) is a feared complication in patients with hematological malignancies. In 2008, the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycosis Study Group (EORTC/MSG) published updated criteria for the diagnostic workup within clinical studies for immunosuppressed patients with suspected fungal infection. We applied these criteria in a routine clinical setting with regard to their feasibility for bedside practice at our institution in a 1-year period. One hundred seventy consecutive patients with a recent history of chemotherapy-induced neutropenia (n = 100) or allogeneic stem cell recipients (n = 70) who had received a CT scan of the chest in search of pulmonary IFD were examined. We analyzed all available radiological and microbiological data according to the EORTC/MSG criteria. The quality of images was good in 94.7 %, microbiological diagnostics performed in 94.1 % patients. Five patients had histopathologic-proven IFD, 18 patients were classified as “probable,” 55 patients as “possible” IFD, and 92 patients did not fulfill any criteria (“no IFD”). Microbiology revealed suggestive findings in 29 patients. These were either galactomannan antigen (Gm-AG) in serum (n = 18) and/or broncho-alveolar lavage (BAL) (n = 5). CT scan showed pulmonary infiltrates in 106 patients; 78 were classified as typical for IPA, further discriminated by morphology and number of nodules, as well as additional signs (halo, air crescent, cavity). We observed a better overall survival in patients without infiltrates compared to those with any type of infiltrate (p = 0.042) and a trend toward favorable survival in patients who had micronodular lesions (p = 0.058). We also found a higher probability of Gm-AG positivity in the group of allogeneic stem cell transplantation (allo-SCT) patients (p = 0.001) and a trend toward an association of Gm-AG positivity and positive findings on CT (p = 0.054). The applicability of criteria was good, both with regard to radiological and mycological evidence and sufficient for the categorization of IFD according to EORTC/MSG in the clinical setting. However, our findings suggest that feasibility improves with stringency of mycological workup, which is reflected in the two subgroups. Radiology harvests by far more suggestive findings which can only partly be correlated with mycological evidence. Although feasible, whether the EORTC/MSG criteria are the appropriate tool for early identification of IFD remains open for discussion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34(1):7–14

    Article  CAS  PubMed  Google Scholar 

  2. Austin JH, Muller NL, Friedman PJ, Hansell DM, Naidich DP, Remy-Jardin M et al (1996) Glossary of terms for CT of the lungs: recommendations of the Nomenclature Committee of the Fleischner Society. Radiology 200(2):327–31

    Article  CAS  PubMed  Google Scholar 

  3. Borlenghi E, Cattaneo C, Capucci MA, Pan A, Quaresmini G, Franco F et al (2007) Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates. Ann Hematol 86(3):205–10

    Article  PubMed  Google Scholar 

  4. Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B et al (1997) Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 15(1):139–47

    CAS  PubMed  Google Scholar 

  5. Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L et al (2001) Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19(1):253–9

    CAS  PubMed  Google Scholar 

  6. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12):1813–21

    Article  PubMed Central  PubMed  Google Scholar 

  7. Denning DW (1998) Invasive aspergillosis. Clin Infect Dis 26(4):781–803, quiz 4-5

    Article  CAS  PubMed  Google Scholar 

  8. Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP (2011) The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 52(9):1144–55

    Article  PubMed Central  PubMed  Google Scholar 

  9. Greene R (2005) The radiological spectrum of pulmonary aspergillosis. Med Mycol 43(Suppl 1):S147–54

    Article  PubMed  Google Scholar 

  10. Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O et al (2007) Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 44(3):373–9

    Article  PubMed  Google Scholar 

  11. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K (1996) Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33(1):23–32

    Article  CAS  PubMed  Google Scholar 

  12. Hauggaard A, Ellis M, Ekelund L (2002) Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis. Acta Radiol 43(3):292–8

    Article  CAS  PubMed  Google Scholar 

  13. Kawazu M, Kanda Y, Nannya Y, Aoki K, Kurokawa M, Chiba S et al (2004) Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1– > 3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 42(6):2733–41

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Kuhlman JE, Fishman EK, Siegelman SS (1985) Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis. Radiology 157(3):611–4

    Article  CAS  PubMed  Google Scholar 

  15. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E et al (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41(9):1242–50

    Article  CAS  PubMed  Google Scholar 

  16. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M (2001) Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97(6):1604–10

    Article  CAS  PubMed  Google Scholar 

  17. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ (2004) Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 190(3):641–9

    Article  CAS  PubMed  Google Scholar 

  18. Mennink-Kersten MA, Donnelly JP, Verweij PE (2004) Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 4(6):349–57

    Article  CAS  PubMed  Google Scholar 

  19. Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G et al (2010) Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 95(4):644–50

    Article  PubMed Central  PubMed  Google Scholar 

  20. Park SY, Lee SO, Choi SH, Sung H, Kim MN, Choi CM et al (2010) Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Infect 61(6):492–8

    Article  PubMed  Google Scholar 

  21. Parron M, Torres I, Pardo M, Morales C, Navarro M, Martinez-Schmizcraft M (2008) The halo sign in computed tomography images: differential diagnosis and correlation with pathology findings. Arch Bronconeumol 44(7):386–92

    Article  PubMed  Google Scholar 

  22. Patterson TF (2005) Advances and challenges in management of invasive mycoses. Lancet 366(9490):1013–25

    Article  PubMed  Google Scholar 

  23. Reuter S, Kern W, Zenz C, Kern P (2009) Prognostic factors for invasive aspergillosis in patients with haematological malignancies. Scand J Infect Dis 41(6–7):483–90

    Article  PubMed  Google Scholar 

  24. Segal BH (2009) Aspergillosis. N Engl J Med 360(18):1870–84

    Article  CAS  PubMed  Google Scholar 

  25. Tanriover MD, Ascioglu S, Altun B, Uzun O (2008) Galactomannan on the stage: prospective evaluation of the applicability in routine practice and surveillance. Mycoses

  26. Tunnicliffe G, Schomberg L, Walsh S, Tinwell B, Harrison T, Chua F (2013) Airway and parenchymal manifestations of pulmonary aspergillosis. Respir Med 107(8):1113–23

    Article  PubMed  Google Scholar 

  27. Weisser M, Rausch C, Droll A, Simcock M, Sendi P, Steffen I et al (2005) Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies. Clin Infect Dis 41(8):1143–9

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christina T. Rieger.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rieger, H., Lustig, D., Barlow, S. et al. Applicability of the EORTC/MSG criteria for IFD in clinical practice. Ann Hematol 94, 847–855 (2015). https://doi.org/10.1007/s00277-014-2282-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2282-y

Keywords

Navigation